| 1. |
Tachihara M, Tsujino K, Ishihara T, Hayashi H, Sato Y, Kurata T, Sugawara S, Shiraishi Y, Teraoka S, Azuma K, Daga H, Yamaguchi M, Kodaira T, Satouchi M, Shimokawa M, Yamamoto N, Nakagawa K, Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial, JAMA oncology, doi: 10.1001/jamaoncol.2023.3309., 9, 11, 1505-1513, 2023.11, Importance: Administration of durvalumab after concurrent chemoradiotherapy is the standard treatment of unresectable, locally advanced non-small cell lung cancer (NSCLC); however, 20% to 30% of patients do not receive durvalumab because of adverse events (AEs) during concurrent chemoradiotherapy. In addition, radiotherapy and immunotherapy have a synergistic effect.
Objective: To investigate the efficacy and safety of durvalumab immunotherapy plus concurrent radiotherapy followed by maintenance with durvalumab therapy for treatment of locally advanced NSCLC without chemotherapy.
Design, setting, and participants: The multicenter, single-arm DOLPHIN (Phase II Study of Durvalumab [MEDI4736] Plus Concurrent Radiation Therapy in Advanced Localized NSCLC Patients) nonrandomized controlled trial was performed by 12 institutions in Japan from September 13, 2019, to May 31, 2022. Participants in the primary registration phase included 74 patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, locally advanced NSCLC. The current analyses were conducted from June 1, 2022, to October 31, 2022.
Interventions: Patients received radiotherapy (60 Gy) in combination with concurrent and maintenance durvalumab immunotherapy, 10 mg/kg every 2 weeks, for up to 1 year.
Main outcomes and measures: The primary end point of the rate of 12-month progression-free survival (PFS), as assessed by an independent central review, was estimated using the Kaplan-Meier method and evaluated with 90% CIs calculated using the Greenwood formula. The key secondary end points were PFS, objective response rate, treatment completion rate, and AEs.
Results: Data from 35 patients (median [range] age, 72 [44-83] years; 31 [88.6%] men) were included in the full analysis set of the evaluable population. The 12-month PFS rate was 72.1% (90% CI, 59.1%-85.1%), and the median PFS was 25.6 months (95% CI, 13.1 months to not estimable) at a median follow-up of 22.8 months (range, 4.3-31.8 months). Scheduled radiation therapy was completed in 97.1% of patients. The confirmed objective response rate was 90.9% (95% CI, 75.7%-98.1%), and the treatment completion rate was 57.6% (95% CI, 39.2%-74.5%). Among 34 patients evaluated in the safety analysis set, AEs of grade 3 or 4 occurred in 18 patients (52.9%), and of grade 5 in 2 patients (5.9%). Pneumonitis or radiation pneumonitis of any grade occurred in 23 patients (67.6%), and of grades 3 or 4 in 4 patients (11.8%).
Conclusions and relevance: Findings from this phase 2 nonrandomized controlled trial indicate that durvalumab immunotherapy combined with curative radiotherapy for patients with PD-L1-positive, unresectable, locally advanced NSCLC is a promising treatment with tolerable AEs and is appropriate as a study treatment for phase 3 clinical trials.. |
| 2. |
Shiraishi Y, Tokito T, Toyozawa R, Inagaki C, Nokihara H, Kawashima Y, Ohe Y, Okamoto I., Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, doi: 10.1016/j.jtho.2023.10.010., 19, 2, 337-343, 2024.02, We conducted a phase 3 clinical trial to compare the efficacy of platinum-based combination chemotherapy together with nivolumab plus ipilimumab relative to that of platinum-based combination chemotherapy together with pembrolizumab in previously untreated patients with advanced NSCLC. The trial was terminated prematurely after treatment of 295 patients because of a high proportion of treatment-related deaths, three of which were due to cytokine release syndrome (CRS), in the nivolumab plus ipilimumab treatment arm. In addition, we encountered two cases of CRS that were effectively managed, for a total of five cases (3.4%) among the 148 patients in the nivolumab plus ipilimumab arm. We here provide details of these five cases. Although patient background and timing of CRS onset differed, fever was observed before the emergence of CRS in all five cases. Oncologists should thus be aware that the development of fever during treatment of patients with nivolumab plus ipilimumab may herald the onset of CRS.. |
| 3. |
Shiraishi Y, Kishimoto J, Sugawara S, Mizutani H, Daga H, Azuma K, Matsumoto H, Hataji O, Nishino K, Mori M, Shukuya T, Saito H, Tachihara M, Hayashi H, Tsuya A, Wakuda K, Yanagitani N, Sakamoto T, Miura S, Hata A, Okada M, Kozuki T, Sato Y, Harada T, Takayama K, Yamamoto N, Nakagawa K, Okamoto I., Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial, JAMA oncology, doi: 10.1001/jamaoncol.2023.5258., 10, 3, 315-324, 2024.03, Importance: The combination of an antibody to programmed cell death-1 (PD-1) or to its ligand (PD-L1) with chemotherapy is the standard first-line treatment for metastatic non-small cell lung cancer (NSCLC). Bevacizumab is expected to enhance the efficacy not only of chemotherapy but also of PD-1/PD-L1 antibodies through blockade of vascular endothelial growth factor-mediated immunosuppression, but further data are needed to support this.
Objective: To evaluate the efficacy and safety of bevacizumab administered with platinum combination therapy and atezolizumab in patients with advanced nonsquamous NSCLC.
Design, setting, and participants: An open-label phase 3 randomized clinical trial was conducted at 37 hospitals in Japan. Patients with advanced nonsquamous NSCLC without genetic driver alterations or those with genetic driver alterations who had received treatment with at least 1 approved tyrosine kinase inhibitor were enrolled between January 20, 2019, and August 12, 2020.
Interventions: Patients were randomly assigned to receive either atezolizumab plus carboplatin with pemetrexed (APP) or atezolizumab, carboplatin plus pemetrexed, and bevacizumab (APPB). After 4 cycles of induction therapy, maintenance therapy with atezolizumab plus pemetrexed or with atezolizumab, pemetrexed, and bevacizumab was administered until evidence of disease progression, development of unacceptable toxic effects, or the elapse of 2 years from the initiation of protocol treatment.
Main outcomes and measures: The primary end point was progression-free survival (PFS) as assessed by blinded independent central review (BICR) in the intention-to-treat (ITT) population.
Results: A total of 412 patients were enrolled (273 men [66%]; median age, 67.0 [range, 24-89] years) and randomly assigned, with 205 in the APPB group and 206 in the APP group of the ITT population after exclusion of 1 patient for good clinical practice violation. The median BICR-assessed PFS was 9.6 months with APPB vs 7.7 months with APP (stratified hazard ratio [HR], 0.86; 95% CI, 0.70-1.07; 1-sided stratified log-rank test; P = .92). According to prespecified subgroup analysis of BICR-assessed PFS, an improved PFS with APPB vs APP was apparent specifically in driver oncogene-positive patients (median, 9.7 vs 5.8 months; stratified HR, 0.67; 95% CI, 0.46-0.98). Toxic effects related to bevacizumab were increased in the APPB group.
Conclusions and relevance: The findings of this trial did not show superiority of APPB over APP for patients with nonsquamous NSCLC; however, this regimen showed a similar tolerability and improved survival relative to APP in patients with driver oncogenes.. |
| 4. |
Nakamichi S, Kubota K, Misumi T, Kondo T, Murakami S, Shiraishi Y, Imai H, Harada D, Isobe K, Itani H, Takata S, Wakui H, Misumi Y, Ikeda S, Asao T, Furuya N, Hosokawa S, Kobayashi Y, Takiguchi Y, Okamoto H., Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study), Clinical cancer research : an official journal of the American Association for Cancer Research, doi: 10.1158/1078-0432.CCR-23-2568., 30, 6, 1104-1110, 2024.05, Purpose: Concurrent chemoradiotherapy (CCRT) followed by durvalumab consolidation for up to 12 months is the standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC). However, exactly when to initiate durvalumab therapy after chemoradiation completion remains unknown. We evaluated the efficacy and safety of durvalumab, administered immediately after CCRT completion, for patients with unresectable stage III NSCLC.
Patients and methods: This study was a prospective, single-arm, open-label phase II clinical trial. Patients without disease progression after definitive CCRT (two cycles of platinum-based doublet chemotherapy with 60 Gy/30 Fr radiotherapy) received durvalumab (every 2 weeks for up to 12 months) from the next day (up to 5 days) after the final radiation dose. The primary endpoint was the 1-year progression-free survival (PFS) from registration before the start of CCRT.
Results: From January 2020 to August 2020, 47 of 50 enrolled patients were evaluable for treatment efficacy and safety. The 1-year PFS from registration was 75.0% [60% confidence interval (CI), 69.0-80.0 and 95% CI, 59.4-85.3]. The objective response rate throughout the study treatment and median PFS from registration were 78.7% and 14.2 months (95% CI, 13.4 to not reached), respectively. Grade 3/4 pneumonitis and febrile neutropenia were each 4.3%.
Conclusions: Our study met the primary endpoint. The incidence of pneumonitis was similar to that of a Japanese subset in the PACIFIC study. Our data support the efficacy and safety of durvalumab administered immediately after the completion of CCRT for patients with unresectable stage III NSCLC.. |
| 5. |
Hazama D, Nakahama K, Kodama H, Miyazaki A, Azuma K, Kawashima Y, Sato Y, Ito K, Shiraishi Y, Miura K, Takahama T, Oizumi S, Namba Y, Ikeda S, Yoshioka H, Tsuya A, Yasuda Y, Negi Y, Hara A, Toda M, Tachihara M. , Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma, JTO clinical and research reports, doi: 10.1016/j.jtocrr.2023.100613., 5, 1, 100613, 2023.11, Introduction: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of lung cancer associated with poor prognosis and resistance to conventional chemotherapy. Immune checkpoint inhibitors (ICIs), alone or in combination with chemotherapy, were found to have clinical benefits in PSC in recent studies. Nevertheless, because these studies included a small number of patients owing to disease rarity, larger studies are needed to evaluate the effectiveness and safety of ICI-based therapy for PSC.
Methods: This multicenter retrospective study evaluated patients with ICI-naive advanced or metastatic PSC who were treated with ICI-based therapy at 25 hospitals in Japan.
Results: A total of 124 patients were evaluated. The overall response rate, median progression-free survival (PFS), and median overall survival (OS) were 59.0%, 10.5 months, and 32.8 months, respectively. The PFS and OS rates at 24 months were 35.3% and 51.5%, respectively. Programmed death-ligand 1 expression, concomitant chemotherapy, and the treatment line were not significantly associated with PFS or OS. Immune-related adverse events (irAEs) were observed in 70 patients (56.5%), including 30 (24.2%) with grade 3 to 5 events. Patients with mild irAEs (grades 1-2) had longer PFS and OS than did those with severe (grades 3-5) or no irAEs. In a multivariate analysis, any-grade irAEs and the absence of liver metastases were independently associated with PFS, whereas any-grade irAEs and Eastern Cooperative Oncology Group performance status less than or equal to 1 were independently associated with OS.
Conclusions: ICI-based therapy was found to have promising effectiveness in patients with advanced or metastatic PSC, regardless of programmed death-ligand 1 expression, concomitant chemotherapy, or treatment line.. |
| 6. |
Inutsuka Y, Iwama E, Shiraishi Y, Yoneshima Y, Shibahara D, Tanaka K, Okamoto I., Osimertinib readministration for central nervous system metastases in non-small cell lung cancer positive for EGFR activating mutations, Respiratory investigation, doi: 10.1016/j.resinv.2024.02.001., 62, 3, 334-338, 2024.05, Background: Osimertinib shows pronounced efficacy for EGFR mutation-positive non-small cell lung cancer (NSCLC) including associated central nervous system (CNS) metastases. Tumors inevitably develop resistance to the drug, however. Osimertinib is sometimes readministered after completion of standard chemotherapy. To clarify which patients might receive benefit from osimertinib readministration, we have retrospectively assessed its efficacy with a focus on CNS metastases.
Methods: A retrospective analysis of medical records was performed for 21 patients who underwent osimertinib readministration at Kyushu University Hospital between March 2016 and April 2023. CNS metastases were evaluated according to modified Response Evaluation Criteria in Solid Tumors (RECIST).
Results: Among the 21 enrolled patients, 16 individuals had target lesions on the basis of RECIST. One (6.3%) of these 16 patients achieved a partial response to osimertinib readministration, with the remaining 15 patients showing stable or progressive disease. The median overall progression-free survival (PFS) and median overall survival for all 21 patients were 3.8 and 13.9 months, respectively. The efficacy of osimertinib readministration for CNS metastases was evaluable in eight patients including five individuals with leptomeningeal metastases. The objective response rate for CNS metastases and the improvement rate for leptomeningeal metastases were both 100%. The median PFS with regard to CNS or non-CNS lesions for these eight patients was 24.7 and 10.5 months, respectively.
Conclusions: Osimertinib readministration showed limited efficacy for non-CNS lesions but excellent efficacy for CNS metastases, suggesting that such treatment is an option for EGFR-mutated NSCLC patients with CNS metastases.. |
| 7. |
Haratani K, Nakamura A, Mamesaya N, Sawa K, Shiraishi Y, Saito R, Tanizaki J, Tamura Y, Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Tokito T, Nagata K, Masuda T, Nakamura Y, Sakai K, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H., Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer., British journal of cancer, doi: 10.1038/s41416-024-02662-2., 2024.03, Background: Immune-related adverse events (irAEs) have been found to predict PD-L1 inhibitor efficacy in metastatic NSCLC. However, the relation of irAEs to clinical outcome for nonmetastatic NSCLC has remained unknown.
Methods: In this multicenter prospective study of Stage III NSCLC treated with PACIFIC regimen, the relation of irAEs to PFS was evaluated by 8-week landmark analysis to minimise lead-time bias as well as by multivariable analysis adjusted for baseline factors. irAEs were categorised as mild or nonmild according to whether they were treated with systemic steroid.
Results: Median PFS was 16.0 months, not reached, and 9.7 months for patients without (85 cases) or with mild (21 cases) or nonmild (21 cases) irAEs, respectively. Multivariable analysis indicated that nonmild irAEs were associated with poor PFS, with HRs of 3.86 (95% CI, 1.31-11.38) compared with no irAEs and 11.58 (95% CI, 2.11-63.63) compared with mild irAEs. This pattern was consistent after irAE grade, the number of durvalumab doses and immune profiles (PD-L1 score, CD8+ tumour-infiltrating lymphocyte density, and tumour mutation burden) were taken into consideration.
Conclusions: The development of mild irAEs might predict a better survival outcome, whereas immunosuppressive steroid-treated irAEs were associated with a worse outcome, regardless of baseline clinical and immune profiles.. |
| 8. |
Yamamoto Y, Shibahara D, Mori T, Otsubo K, Shiraishi Y, Yoneshima Y, Iwama E, Tanaka K, Oda Y, Okamoto I., Tracheomediastinal fistula induced by concurrent chemoradiotherapy in small cell lung cancer: A case report and literature review., Thorac Cancer, doi: 10.1111/1759-7714.15270, 15, 13, 1106-1111, 2024.03, Tracheomediastinal fistula is a rare but life-threatening complication of cancer. We report a case of tracheomediastinal fistula induced by concurrent chemoradiotherapy in limited stage small cell lung cancer. Despite the treatment response, the metastatic paratracheal lymph node increased gradually during concurrent chemoradiotherapy, resulting in the occurrence of tracheomediastinal fistula and mediastinitis. Without any surgical intervention, the patient achieved successful recovery from mediastinitis through antibiotic treatment, although the tracheomediastinal fistula remained open. In this report, we also review previous studies of tracheomediastinal and bronchomediastinal fistulas and summarize the clinical features.. |
| 9. |
Nakatsuru K, Tsubouchi K, Hirahata M, Nakashima T, Takahata Y, Okamatsu Y, Shiraishi Y, Okamoto I, Harada T., Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum-based chemotherapy., Thorac Cancer., 2023.07. |
| 10. |
Tsutsumi H, Inoue H, Shiraishi Y, Hirayama A, Nakanishi T, Ando H, Nakajima M, Shinozaki S, Ogata H, Okamura K, Kimura S, Ogawa T, Ota K, Yoneshima Y, Tanaka K, Hamada N, Okamoto I, Iwama E., Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors., Lung Cancer., 2023.06. |
| 11. |
Oku Y, Toyokawa G, Wakasu S, Kinoshita F, Takamori S, Watanabe K, Haratake N, Nagano T, Kosai K, Takada K, Fujimoto A, Higashijima K, Shiraishi Y, Tanaka K, Takeoka H, Okamoto M, Yamashita T, Shimokawa M, Shoji F, Yamazaki K, Okamoto T, Seto T, Ueda H, Takeo S, Nakashima N, Okamoto I, Takenaka T, Yoshizumi T., Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small-cell lung cancer patients., Cancer Med, 2023.06. |
| 12. |
Fujimoto D, Miura S, Tomii K, Sumikawa H, Yoshimura K, Wakuda K, Oya Y, Yokoyama T, Kijima T, Asao T, Tamiya M, Nakamura A, Yoshioka H, Tokito T, Murakami S, Tamiya A, Yokouchi H, Watanabe S, Yamaguchi O, Morinaga R, Jodai T, Ito K, Shiraishi Y, Kogure Y, Shibaki R, Yamamoto N., Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer., Sci Rep., 2023.03. |
| 13. |
Goto K, Shiraishi Y, Murakami H, Horinouchi H, Toyozawa R, Takeda M, Uno M, Crawford N, McGill J, Jimbo T, Ishigami M, Takayama G, Nakayama S, Ohwada S, Nishio M., Phase 1 study of DS-1205c combined with gefitinib for EGFR mutation-positive non-small cell lung cancer., Cancer Med., 2023.01. |
| 14. |
Shiraishi Y, Shimose T, Tsuchiya-Kawano Y, Ishii H, Daga H, Ito K, Saruwatari K, Okamoto I., Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases., Cancer Manag Res., 2022.10. |
| 15. |
Ibusuki R, Yoneshima Y, Hashisako M, Matsuo N, Harada T, Tsuchiya-Kawano Y, Kishimoto J, Ota K, Shiraishi Y, Iwama E, Tanaka K, Oda Y, Okamoto I., Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer., Transl Lung Cancer Res., 2022.11. |
| 16. |
Shiraishi Y, Kishimoto J, Shimose T, Toi Y, Sugawara S, Okamoto I., Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial., 2022.07. |
| 17. |
Taniguchi Y, Shimokawa T, Takiguchi Y, Misumi T, Nakamura Y, Kawashima Y, Furuya N, Shiraishi Y, Harada T, Tanaka H, Miura S, Uchiyama A, Nakahara Y, Tokito T, Naoki K, Bessho A, Goto Y, Seike M, Okamoto H., A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630., Clin Cancer Res., 10.1158/1078-0432.CCR-22-1687, 2022.10. |
| 18. |
Furuyama K, Harada T, Iwama E, Shiraishi Y, Okamura K, Ijichi K, Fujii A, Ota K, Wang S, Li H, Takayama K, Giaccone G, Nakanishi Y., Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors., Cancer science, 10.1111/cas.12125, 104, 5, 584-589, 2013.05. |
| 19. |
Toyokawa G, Takenoyama M, Taguchi K, Toyozawa R, Inamasu E, Kojo M, Shiraishi Y, Morodomi Y, Takenaka T, Hirai F, Yamaguchi M, Seto T, Shimokawa M, Ichinose Y., An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene., Lung Cancer, 10.1016/j.lungcan.2013.05.022, 81, 3, 487-490, 2013.07. |
| 20. |
Toyokawa G, Takenoyama M, Taguchi K, Arakaki K, Inamasu E, Toyozawa R, Kojo M, Shiraishi Y, Morodomi Y, Takenaka T, Hirai F, Yamaguchi M, Seto T, Leone A, Graziano P, Ichinose Y., The first case of lung carcinosarcoma harboring in-frame deletions at exon19 in the EGFR gene., Lung cancer, 10.1016/j.lungcan.2013.06.013, 81, 3, 491-494, 2013.09. |
| 21. |
Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, Morodomi Y, Shiraishi Y, Takenaka T, Yamaguchi M, Shimokawa M, Seto T, Ichinose Y., Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy., International journal of clinical oncology, 10.1007/s10147-013-0619-5, 19, 4, 601-606, 2014.08. |
| 22. |
Hirai F, Seto T, Shimokawa M, Inamasu E, Toyozawa R, Toyokawa G, Yoshida T, Shiraishi Y, Takenaka T, Yamaguchi M, Takenoyama M, Ichinose Y., Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer., Anticancer research, 2014.02. |
| 23. |
omoyoshi Takenaka, Mitsuhiro Takenoyama, Masafumi Yamaguchi, Ryo Toyozawa, Eiko Inamasu, Miyako Kojo, Gouji Toyokawa, Tsukihisa Yoshida, Yoshimasa Shiraishi, Yosuke Morodomi, Fumihiko Hirai, Kenichi Taguchi, Mototsugu Shimokawa, Takashi Seto, Yukito Ichinose, Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer, European Journal of Cardio-thoracic Surgery, 10.1093/ejcts/ezu227, 47, 3, 550-555, 2015.03. |
| 24. |
Ogata H, Harada E, Moriya S, Fukuyama S, Suzuki K, Shiraishi Y, Ando H, Uryu K, Shinozaki S, Ide M, Sakamoto A, Nakanishi T, Hamada N, Yoneshima Y, Ota K, Kohashi K, Tateishi Y, Miyashita Y, Oda Y, Matsumoto K., Pleuropulmonary Paragonimiasis with Multiple Nodules in the Pleura, INTERNAL MEDICINE, 10.2169/internalmedicine.4457-20, 59, 15, 1879-1881. |
| 25. |
Li H, Takayama K, Wang S., Shiraishi Y., Gotanda K., Harada T., Furuyama K., Iwama E., Okamoto I, Nakanishi Y, Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression., Cancer Chemother Pharmacol. , 74, 6, 1297-1305, 2014.12. |
| 26. |
Shiraishi Yoshimasa, Kishimoto Junji, Tanaka Kentaro, Sugawara Shunichi, Daga Haruko, Hirano Katsuya, Azuma Koichi, Hataji Osamu, Hayashi Hidetoshi, Tachihara Motoko, Mitsudomi Tetsuya, Seto Takashi, Nakagawa Kazuhiko, Yamamoto Nobuyuki, Okamoto, Isamu, Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer, CLINICAL LUNG CANCER, 10.1016/j.cllc.2020.03.010, 21, 5, 472-476, 2020.09. |
| 27. |
Akamatsu H, Teraoka S, Takamori S, Miura S, Hayashi H, Hata A, Toi Y, Shiraishi Y, Mamesaya N, Sato Y, Furuya N, Oyanagi J, Koh Y, Misumi T, Yamamoto N, Nakagawa K., Nivolumab retreatment in non-small cell lung cancer patients who responded to prior immune-checkpoint inhibitors and had ICI-free intervals (WJOG9616L)., Clinical cancer research, 10.1158/1078-0432.CCR-22-0602., 2022.06. |
| 28. |
Koichi Takayama, Masafumi Takeshita, Koji Inoue, Masao Ichiki, Masaki Fujita, Taishi Harada, Yoshimasa Shiraishi, Hiroshi Wataya, Shoji Tokunaga, Tadaaki Yamada, Junji Uchino, Kenji Sugio, Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801, Oncologist, 10.1634/theoncologist.2020-0322, 25, 8, 1146-1157, 2020.08. |
| 29. |
Kaname Nosaki, Takeharu Yamanaka, Akinobu Hamada, Yoshimasa Shiraishi, Taishi Harada, Daisuke Himeji, Takeshi Kitazaki, Noriyuki Ebi, Takayuki Shimose, Takashi Seto, Mitsuhiro Takenoyama, Kenji Sugio, Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101), Oncologist, 10.1634/theoncologist.2020-0640, 12, 1869-1878, 2020.12. |
| 30. |
Tsuchiya-Kawano Yuko, Shiraishi Yoshimasa, Kiyomi Fumiaki, Okamoto Isamu, Phase II Study of Nivolumab Plus Ipilimumab with Platinum-Based Chemotherapy for Treatment-Naive Advanced Non-Small Cell Lung Cancer with Untreated Brain Metastases: NIke Trial (LOGiK2004), CANCER MANAGEMENT AND RESEARCH, 10.2147/CMAR.S341287, 13, 8489-8493, 2021.11. |
| 31. |
Takao Tomoaki, Tanaka Kentaro, Shiraishi Yoshimasa, Ota Keiichi, Yoneshima Yasuto, Iwama Eiji, Okamoto Isamu, Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone, CLINICAL LUNG CANCER, 10.1016/j.cllc.2021.03.003, 22, 5, E784-E785, 2021.09. |
